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We prepared a 5-fluorodeoxyuridine (5-FdUrd) derivative possessing azide methyl 
group (N3-FdUrd) as a novel radiation-activated prodrug. The parent antitumor agent, 
5-FdUrd, was released efficiently from N3-FdUrd by hypoxic X-irradiation. On the 
other hand, the activation of N3-FdUrd was suppressed upon X-irradiation under aerobic 
conditions. A biological assay using A549 cells revealed that the cytotoxicity of 
N3-FdUrd was significantly enhanced by hypoxic X-irradiation.    
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Prodrugs that are activated by an external stimulus have been attracting much attention. 
These prodrugs themselves are nontoxic, but exposure to triggers such as 
photoirradiation,1 change in pH2 or enzymatic reactions3 bring about changes in the 
chemical structure of the prodrugs to enable their inherent medical capability.4 Because 
of the ease of controlling their functions, stimuli-sensitive prodrugs are prospective 
high-performing medical agents with mild side effects. 
One of the new strategies employed in this area is the utilization of X-irradiation5 as an 
external trigger to activate prodrugs. Since chemical reactions triggered by radiation can 
be controlled spatially and temporary, such prodrugs can be converted to their active 
forms with exact control of the area, time, and dosage. Recently, we have developed 
several prodrugs that can be activated by X-irradiation.6 We prepared prodrugs of the 
antitumor agents 5-fluorouracil, 5-fluorodeoxyuridine (5-FdUrd), and cytarabine by 
incorporation of a 2-oxoalkyl group or an indolequinone structure, which are removable 
by X-ray treatment under hypoxic conditions. A reaction mechanism has been proposed: 
these substituents undergo reductive activation by reducing species generated by the 
radiolysis of water7 to release their parent drug. These prodrugs showed cytotoxicity 
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towards hypoxic tumor cells upon X-irradiation, while they were nontoxic against 
aerobic cells, even upon X-irradiation. 
Herein, we discuss the design of a novel radiation-activated prodrug of 5-FdUrd 
possessing azide methyl group (N3-FdUrd), which is known to be a removable 
substituent under reducing conditions.8 We expected that N3-FdUrd would be activated 
by reducing species generated from radiolysis of water to form aminal 1 (Figure 1), 
which would be hydrolyzed in aqueous solution to give 5-FdUrd. We synthesized the 
N3-FdUrd and characterized its radiolytic reduction behavior. The radation-dependent 
cytotoxicity of N3-FdUrd using living cells was also assessed. 
The strategy for preparation of N3-FdUrd is summarized in Scheme 1. 
Diacetyl-5-fluorodeoxyuridine 2 was coupled with chloromethyl methyl sulfide, and 
then converted to the azide compound 4.9 Hydrolysis of 4 under basic conditions 







Initially, we performed the radiolytic reduction of N3-FdUrd and monitored the reaction 
using reversed-phase HPLC.11 We conducted the radiolysis in argon-purged aqueous 
solutions containing 2-methyl-2-propanol as a scavenger for the oxidizing hydroxyl 
radicals (OH•). Under these conditions, hydrated electrons (eaq–) and hydrogen atoms 
(H•) are generated as the major reducing species from the radiolysis of water. As shown 
in Figure 2, a single new signal appeared during radiolysis under hypoxic conditions, 
while the starting material, N3-FdUrd, disappeared. The product was identified as the 
parent 5-FdUrd, according to the overlapped injection of authentic samples in the HPLC 
analysis. The G values were estimated to be 159 nmol/J for the formation of the 
corresponding 5-FdUrd and 336 nmol/J for the decomposition of N3-FdUrd; thus, 47% 
of the decomposed N3-FdUrd was converted to 5-FdUrd upon hypoxic X-irradiation. To 
verify the reaction mechanism in detail, we next conducted a similar radiolytic 
reduction of N3-FdUrd under aerobic conditions. In contrast to the efficient activation of 
hypoxic irradiation, both formation of 5-FdUrd and decomposition of N3-FdUrd were 
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markedly suppressed, as shown in Figure 2b. The G values were 50 nmol / J for the 
formation of 5-FdUrd and 118 nmol / J for the decomposition of N3-FdUrd. It has been 
well-characterized that molecular oxygen captures both eaq– and H•.12 Thus, it is most 
likely that eaq– and H• are key reactive species for the activation of N3-FdUrd and the 




We then assessed the cytotoxicity of N3-FdUrd and 5-FdUrd towards A549 cells (human 
lung adenocarcinoma). A cell viability assay was employed to test the cytotoxicity in 
vitro. The IC50 value was defined as the concentration required to reduce the viability of 
the cells by 50%, and was estimated on exposure to N3-FdUrd and 5-FdUrd.13 Figure 3 
shows the survival curve of the A549 cells incubated in the presence of drugs at various 
concentrations in air containing 5% CO2 for 72 h at 37 ˚C. The IC50 values were 1.47 
and 0.047 M for N3-FdUrd and 5-FdUrd, respectively, indicating that incorporation of 
an azide methyl group into 5-FdUrd at the N(3)-position is responsible for the decrease 
 8




The properties of N3-FdUrd described above prompted us to further investigate the 
effect of X-irradiation on the cytotoxicity (Figure 4A). An aqueous solution of 
N3-FdUrd was X-irradiated under hypoxic or aerobic conditions, and then the resulting 
solution was administered to the A549 cells.14 In accordance with the suppression of the 
cytotoxic effects mentioned above, administration of 200 nM N3-FdUrd did not bring 
about a cytocidal action. We also confirmed that the X-irradiated N3-FdUrd under 
aerobic conditions did not show any cytotoxic effect, consistent with the results that 
radiolytic activation is suppressed under aerobic conditions. It is striking that the cell 
viability was significantly reduced in the presence of hypoxically irradiated N3-FdUrd. 
These results strongly indicate that 5-FdUrd released from N3-FdUrd upon hypoxic 





In light of the effect of X-irradiation, further attempts were made to verify the function 
of N3-FdUrd as a radiation-activated prodrug. We exposed A549 cells to X-rays under 
hypoxic conditions in the presence or absence of N3-FdUrd and characterized the 
radiation-dependent cytotoxic effect of N3-FdUrd.15 As shown in Figure 4B, the cells 
were viable even in the presence of 100 nM N3-FdUrd without X-irradiation. Although 
the hypoxic cells showed high viability even upon X-irradiation owing to their 
resistibility, radiation in the presence of N3-FdUrd significantly enhanced the radiation 
sensitivity of the A549 cells, resulting in low cell viability. Thus, N3-FdUrd released 
toxic 5-FdUrd via radiolytic reduction in hypoxic cells, which led to an enhanced 
cytotoxicity.  
In summary, we have synthesized a 5-FdUrd derivative possessing azide methyl group 
at the N(3)-position (N3-FdUrd) and characterized its properties upon X-irradiation. 
N3-FdUrd was activated to release 5-FdUrd in a hypoxia-selective manner via reduction 
by H• and eaq–, which were generated by the radiolysis of water. A cytotoxicity assay 
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using A549 cells revealed that N3-FdUrd showed a lower toxicity. On the other hand, 
X-irradiation resulted in a formation of 5-FdUrd in hypoxic cells, leading to the 
enhancement of the radiation sensitivity of A549 cells. Thus, N3-FdUrd is a promising 
radiation-activated prodrug with lesser side effects. Further in vivo experiments on 
N3-FdUrd, focusing on practical use, are in progress. 
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Scheme 1. Reagents and conditions: (a) Chloromethylmethylsulfide, NaH, DMF, 2 h, 
r.t., 78%; (b) NCS, TMSCl, 2 h, r.t., CH2Cl2; (c) NaN3, DMF, 48 h, r.t., 17% (2 steps); 



















Figure 2. (A,B) HPLC profiles for the reductive activation of N3-FdUrd (300 M) by 
X-irradiation (0, 240, 480 and 960 Gy). The radiolysis of aqueous solution containing 
15 mM 2-methyl-2-propanol was conducted under hypoxic (A) or aerobic (B) 
conditions. (C) Release of 5-FdUrd from N3-FdUrd (300 M) in the hypoxic (circle) or 






































Figure 3. Cytotoxicity of N3-FdUrd (circle) and 5-FdUrd (triangle) against A549 tumor 
cells. A549 cells were incubated with indicated concentrations of N3-FdUrd or 5-FdUrd 
under aerobic conditions for 72 h. The cell viability was calculated by means of cell 





















                                
Figure 4. Radiation-induced cytotoxicity of N3-FdUrd against A549 cells. (A) Aqueous 
solutions of N3-FdUrd (0 nM: - or 200 nM: +) was X-irradiated (6 Gy) under aerobic or 
hypoxic condiitons, and then administered to cells. (B) A549 cells were cultured in the 
presence or absence of 100 nM N3-FdUrd, and treated with X-ray (6 Gy) under hypoxic 
conditions. Results are shown with the mean ± S.D. (n = 3 for (A), n = 4 for (B))(*P < 
0.05; NS: not significant). 
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